Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Sulanda (surufatinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Hutchmed

Drug class:

VEGFR inhibitor, FGFR1 inhibitor

Related drugs:

›

No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1
PD-L1 underexpression	Gastric Adenocarcinoma	PD-L1 underexpression	Gastric Adenocarcinoma	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
PD-L1 underexpression	Esophageal Squamous Cell Carcinoma	PD-L1 underexpression	Esophageal Squamous Cell Carcinoma	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
PD-L1 expression	Neuroendocrine Tumor	PD-L1 expression	Neuroendocrine Tumor	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3